| |
|
CritiTech Announces
New CEO
June 4, 2009
FOR IMMEDIATE RELEASE
LAWRENCE, Kan. CritiTech's Chairman and President,
Sam Campbell announced today that Dr. David Johnston has been
named CritiTech's CEO. Dr. Johnston is a highly qualified
executive with extensive leadership experience in non-clinical
chemistry (chemistry, pharmaceutical product development)
and clinical development (Phase I through Phase IV), regulatory
approval, technology transfer, international operations, sales
and marketing, and brand management. Campbell says, "With
Dr. Johnston's extensive experience, he will help elevate
and expand CritiTech's ability to develop and commercialize
pharmaceutical products." Dr. Johnston most recently
served as the interim President and CEO for AerovectRX, Inc.,
a spin out from the Center for Disease Control. Previously,
he served as Sr. Vice President of R&D for Nektar Therapeutics
with responsibility for Nektar's research and development
activities world-wide. In addition to his R&D responsibilities,
he was Director of Nektar ( UK ), Chairman of Nektar India
(Pvt.) Ltd., and a member of the Joint Development Committees
for all of their leading pharmaceutical partnerships. Prior
to this role, he was chief development officer for Control
Delivery Systems. He formerly was President and COO of AAI
International directing all of the CRO business in North America,
Europe, and Mainland China. Dr. Johnston has held international
leadership positions with Oread, Inc., Sanofi-Winthrop and
Sterling Winthrop and is currently on the board of Wilmington
Pharmaceuticals and the advisory board of Velquest Inc.
Dr. Johnston received his Ph.D. in Organic Chemistry from
St. Andrews University , St. Andrews Scotland and did his
Post Doctoral Studies at Max Planck Institute, Heidelberg,
Germany.
CritiTech, Inc. currently has their oncology drug Nanotax®
in a Phase I Clinical Trial at the Kansas University Cancer
Center and is progressing with additional drug candidates
in preclinical stages. CritiTech, Inc. opened its laboratory
in June, 2004 at the West Lawrence Labs located at 4950 Research
Park Way in Lawrence, Kansas. CritiTech provides critical
drug delivery and development technology for the pharmaceutical
industry through its patented nanoparticle production technology
originally developed at the University of Kansas.
|
